Posted by Michael Wonder on 18 Dec 2023
Zai Lab announces the first listing of Vyvgart (efgartigimod alfa) and other updates in China’s National Reimbursement Drug List
12 December 2023 - Zai Lab today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration has been updated to include three medicines.
The three medicines are:
- Vvygart (efgartigimod alfa injection) is included for the first time in the NRDL for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive
- Nuzyra (omadacycline) is included for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
- Zejula (niraparib) is renewed for the maintenance treatment of adult patients with platinum-sensitive, first-line and recurrent ovarian cancer
